drugset / Trial / NCT05215925
A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Combination with Chemotherapy or Monotherapy in Advanced Non-squamous Non-small Cell Lung Cancer (nsqNSCLC) Patients with High EGFR Expression
Timeline
- Start
- 2023-02-01
- Primary completion
- 2023-07-15
- Completion
- 2024-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | PIMURUTAMAB | Monoclonal antibody | 1500 mg | — |
| Subject | Pemetrexed | Small molecule | — | — |